Orbital Therapeutics Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
Orbital Therapeutics is a Cambridge, Massachusetts-based biotechnology company focused on developing RNA medicines designed to reprogram cells in vivo, addressing diseases at their source. The organization relies on a platform that integrates circular and linear RNA, targeted delivery, and AI-guided design to create programmable therapies aligned with the biology of specific diseases. Its lead program, OTX-201, targets autoimmune disease by depleting B cells to reset the immune system, and the platform is positioned for expansion into autoimmune indications, oncology, next-generation vaccines, and protein therapeutics. A small-to-mid-sized biotechnology company, Orbital operates within the broader RNA medicine and biotech research landscape, aiming to collaborate with drug developers to advance therapies. The leadership team brings expertise in RNA science, clinical development, and commercialization. In July 2025, the company presented encouraging preclinical results for OTX-201 at the 5th Annual mRNA-Based Therapeutics Summit in Boston, illustrating progress for its lead RNA immunotherapy.
1-888-653-2347 
support@leadiq.com 
